ANI Pharmaceuticals (ANIP) Q2 Earnings: What To Expect
ANI Pharmaceuticals beat analysts' revenue expectations by 9.8% last quarter, reporting revenues of $197.1 million, up 43.4% year on year. It was a very strong quarter for the company, with a solid beat of analysts' EPS estimates and full-year revenue guidance slightly topping analysts' expectations.
Is ANI Pharmaceuticals a buy or sell going into earnings? Read our full analysis here, it's free.
This quarter, analysts are expecting ANI Pharmaceuticals's revenue to grow 38.7% year on year to $191.5 million, improving from the 18.4% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.42 per share.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. ANI Pharmaceuticals has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 6.9% on average.
Looking at ANI Pharmaceuticals's peers in the pharmaceuticals segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Amneal delivered year-on-year revenue growth of 3.2%, missing analysts' expectations by 2.5%, and Bristol-Myers Squibb reported flat revenue, topping estimates by 7.8%. Amneal's stock price was unchanged after the resultswhile Bristol-Myers Squibb was down 3.9%.
Read our full analysis of Amneal's results here and Bristol-Myers Squibb's results here.
The euphoria surrounding Trump's November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the pharmaceuticals stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 5.7% on average over the last month. ANI Pharmaceuticals is up 6.2% during the same time and is heading into earnings with an average analyst price target of $81.38 (compared to the current share price of $69.09).
Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
擷取數據時發生錯誤
登入存取你的投資組合
擷取數據時發生錯誤
擷取數據時發生錯誤
擷取數據時發生錯誤
擷取數據時發生錯誤
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a minute ago
- Yahoo
The Next Generation of Dividend Kings: 3 Stocks to Watch
Key Points Only 4% of companies in the S&P 500 have delivered dividend growth on par with ExxonMobil. NNN REIT has the third-longest dividend growth streak in the REIT sector. Medtronic is on the cusp of joining this elite group of dividend stocks. 10 stocks we like better than ExxonMobil › Dividend Kings are the most durable dividend stocks, having increased their payouts annually for at least 50 consecutive years. This resilience is impressive, as they've weathered at least seven recessions in that time. The list of current Dividend Kings is short, with only 55 companies. More companies should join this group as they reach the milestone in the coming years. Here are three likely future Dividend Kings. 1. ExxonMobil ExxonMobil (NYSE: XOM) is steadily marching toward Dividend King status. The oil giant has now increased its dividend for 42 straight years, the longest current streak in the oil patch. Only 4% of companies in the S&P 500 (SNPINDEX: ^GSPC) have delivered dividend growth of 42 or more years. The energy company has put itself in a strong position to continue increasing its dividend. ExxonMobil's plan to 2030 aims to deliver the growth potential of $20 billion in earnings and $30 billion in cash flow by the dawn of the next decade. That has it on track to deliver compound annual growth rates of 10% for earnings and 8% for its cash flow over the next five years. Exxon aims to deliver this robust growth by investing $140 billion into higher-return major capital projects and its Permian Basin development program. It also expects to achieve another $7 billion in structural cost savings by 2030, compared to the third quarter of last year. Exxon is also building the energy company of the future by investing in several lower-carbon energy technologies, including hydrogen, carbon capture and sequestration, and lithium. These and other new businesses have the potential to add $3 billion to its earnings by 2030 and $13 billion by 2040. Combine all this with Exxon's fortress financial profile, and the oil giant seems destined to eventually earn the crown of Dividend King. 2. NNN REIT NNN REIT (NYSE: NNN) reached an important milestone last year when the real estate investment trust (REIT) delivered its 35th consecutive dividend increase. Only two other REITs and fewer than 80 publicly traded companies have reached that level. The REIT has since extended its streak to 36 straight years. The landlord has a very simple business model: It invests in single-tenant net leased properties. It acquires properties secured by long-term net leases (initial terms of 10 to 20 years) in prime locations within strong markets. These properties produce very reliable rental income. NNN REIT establishes relationships with expanding retailers, which steadily provide it with new investment opportunities. It typically acquires properties via sale-leaseback transactions. These relationship-based transactions provide clients with capital to continue expanding their retail footprints, which ultimately presents the REIT with new investment opportunities. NNN REIT maintains a conservative financial profile, which allows it to continue expanding its portfolio (and dividend) throughout the economic cycle. 3. Medtronic Medtronic (NYSE: MDT) is close to earning Dividend King status, with 48 straight years of dividend growth. The medical device maker is well-positioned to continue raising its payout. The healthcare company plans to separate its diabetes business over the next 18 months. It ideally plans to complete an initial public offering of the unit and a subsequent split-off of the business. This strategy will allow it to focus all its attention on its growing cardiovascular, neuroscience, and medical-surgical units. Those three markets are large and growing at a mid-to-high single-digit annual rate. Medtronic aims to capture a larger share of these expanding markets by continuing to invest heavily in research and development to launch new and improved products. It also has the balance sheet strength to make acquisitions as the right opportunities arise. These growth investments should increase its cash flow, enabling Medtronic to ascend to the next level of dividend royalty. Three likely future kings ExxonMobil, NNN REIT, and Medtronic are all well on their way to eventually becoming Dividend Kings. They have the financial strength and visible earnings growth potential to continue increasing their dividends for years to come. All this means they're ideal stocks to buy for those seeking durable, steadily rising dividend income. Should you invest $1,000 in ExxonMobil right now? Before you buy stock in ExxonMobil, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and ExxonMobil wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 11, 2025 Matt DiLallo has positions in Medtronic. The Motley Fool recommends Medtronic and recommends the following options: long January 2026 $75 calls on Medtronic and short January 2026 $85 calls on Medtronic. The Motley Fool has a disclosure policy. The Next Generation of Dividend Kings: 3 Stocks to Watch was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a minute ago
- Yahoo
Bitcoin Pulls Back to $119K as Looming Inflation Data Could Bring Price Swings
Bitcoin's (BTC-USD) overnight push towards fresh records met with profit-taking on Monday, knocking prices down to $118,500. The pullback left bitcoin 2.8% off its session high of $122,200, though the largest crypto remained up 0.4% over the past 24 hours. Ether held above $4,200, modestly up 0.8% during the same period, while major altcoins Solana's SOL (SOL), dogecoin (DOGE) and Sui's native token (SUI) slipped 3%-4%. James Van Straten, senior analyst at CoinDesk, noted that bitcoin's weekend rally left a gap in the CME futures market, which trade only on weekdays, between Friday's close at $117,430 and Monday's open at $119,000. History suggests that BTC could pull back to revisit and "fill" that gap, he said. Tuesday's U.S. Consumer Price Index (CPI) report could be the week's biggest catalyst for traders, with Producer Price Index (PPI) data following later in the week. Whether bitcoin's momentum continues will likely depend on those U.S. macroeconomic data reports, Bitfinex analysts said in a Monday market report. "With market sensitivity to macro events running high, traders should prepare for increased volatility and the possibility of a retracement toward $110,000 in the near term," the Bitfinex analysts wrote. "We believe that the ranging conditions and oscillation between the range highs and lows will continue, since price is constantly moving above and below the cost-basis of fresh buyers allowing for charged sentiments around key macro data releases," they in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a minute ago
- Yahoo
On Holding lifts annual outlook after strong Q2 sales beat, shares jump
-- On Holding (NYSE:ONON) shares soared around 10% in premarket trading on Tuesday after the Switzerland-based sportswear maker beat analyst expectations for second-quarter sales and raised its full-year outlook. The company reported a 32% year-over-year increase in net sales to CHF 749.2 million, or 38.2% on a constant currency basis, exceeding consensus expectations of CHF 703.8 million. Adjusted earnings per share (EPS) came in at negative CHF 0.09, well below the analysts' estimate of CHF 0.14. Direct-to-consumer sales rose 47.2% to CHF 308.3 million, up 54.3% on a constant currency basis. Wholesale sales grew 23.1% to CHF 441.0 million, or 28.8% on a constant currency basis. Adjusted EBITDA rose 50% to CHF 136.1 million from CHF 90.8 million a year earlier, with the margin improving to 18.2% from 16.0%. "We're one and a half years into our three-year strategic plan, and the results of our consistent execution and unwavering focus are clearly visible in the outstanding numbers we report today," said Martin Hoffmann, CEO and CFO of On. Citing strong recent performance and greater confidence in its outlook, the company raised full-year guidance across all key metrics. Net sales are now expected to grow at least 31% year-over-year on a constant currency basis, up from at least 28% previously. At current exchange rates, this equates to reported net sales of at least CHF 2.91 billion, compared with CHF 2.86 billion in the prior outlook. The company now sees gross profit margin at 60.5–61.0%, versus 60.0–60.5% previously, and adjusted EBITDA margin at 17.0–17.5%, compared with 16.5–17.5% before. The updated guidance factors in the impact of additional reciprocal tariffs under the U.S. Presidential Executive Order issued on July 31, 2025, On said. Related articles On Holding lifts annual outlook after strong Q2 sales beat, shares jump Victoria's Secret Exposed: The Warning Sign Behind the Stock's 52% Collapse Surge of 50% since our AI selection, this chip giant still has great potential Sign in to access your portfolio
